本文選題：GM1 + 單唾液四已糖神經(jīng)節(jié)苷酯鈉��； 參考：《重慶理工大學(xué)》2017年碩士論文

【摘要】：目的:觀察不同劑量單唾液四已糖神經(jīng)節(jié)苷酯鈉治療腦出血、急性腦梗死、糖尿病周圍神經(jīng)、腦出血的臨床療效及不良反應(yīng)發(fā)生率,進行對比以評估其治療的有效性與安全性,為標(biāo)準(zhǔn)的治療方案的制訂提供科學(xué)依據(jù)。方法:回顧性研究我院2013年03月~2015年03月期間收治的顱腦損傷、急性腦出血、急性腦梗死、糖尿病外周神經(jīng)病變病例。根據(jù)高、中、低三種不同劑量單唾液四已糖神經(jīng)節(jié)苷酯鈉進行治療,觀察病例治療前后臨床療效及其不良反應(yīng)。結(jié)果:1.四組試驗?zāi)X損傷患者在接受治療一周的治療期后,患者在對照組70例恢復(fù)良好,中殘11例,10例重度殘疾,植物生存26例,總有效率77.77%。高劑量治療組98例恢復(fù)良好,中殘7例,其中8例重度殘疾,植物狀態(tài)4例,總有效率為96.58%。中劑量治療的患者94例恢復(fù)良好,其中9例中度殘疾,9例重度殘疾,植物生存5例,總有效率為95.72%。低劑量治療組85例恢復(fù)良好,中殘10例,9例重度殘疾人,植物生存13例,總有效率為88.88%。由此可以看出,治療組的總效率比總有效劑量和治療效果和正相關(guān)顯著高,差異有統(tǒng)計學(xué)意義(P0.05)。四組治療后,比較四組治療顱內(nèi)壓、收縮壓和舒張壓,差異無統(tǒng)計學(xué)意義(P0.05)。2.四組患者急性腦出血指標(biāo)進行比較,具有統(tǒng)計學(xué)顯著差異(P0.05)。3.急性腦梗死組的治療前,沒有顯著差異(P0.05),統(tǒng)計治療組和對照組NIHSS評分和Barthel指數(shù)得分,治療后,有顯著差異意義(P0.05),四組NIHSS評分和Barthel指數(shù)評分在治療前后較對照組顯著高于治療組,在NIHSS評分和Barthel指數(shù)評分之間差值具有統(tǒng)計學(xué)差異(P0.05)。4.糖尿病周圍神經(jīng)病變對照組為76.92%,前高后低劑量治療組中分別為84%,80%,總有效率,顯著高出組之間的差異(P0.05),統(tǒng)計學(xué)差異顯著。結(jié)論:單唾液四已糖神經(jīng)節(jié)苷酯鈉對于改善急性腦出血、急性腦梗死、顱腦損傷、糖尿病外周神經(jīng)病變有效,治療過程中高、中、低三種劑量造成不良反應(yīng)輕微,其治療效果隨著用藥劑量的增加而增加,不良反應(yīng)率也隨著用藥劑量的增加而增加,呈現(xiàn)正相關(guān)趨勢。由于本次實驗病例研究對象較少,且存在一些不足,因此本次實驗研究結(jié)果存在一定的不確定性,這些結(jié)論還有待大量隨機實驗數(shù)據(jù)進一步研究證實。
[Abstract]:Objective: to observe the clinical efficacy and incidence of adverse reactions in the treatment of intracerebral hemorrhage, acute cerebral infarction, diabetic peripheral nerve and intracerebral hemorrhage with different doses of single saliva tetrahexosylganglioside sodium, and to evaluate the efficacy and safety of the treatment. To provide scientific basis for the formulation of standard treatment program. Methods: the patients with craniocerebral injury, acute cerebral hemorrhage, acute cerebral infarction and diabetic peripheral neuropathy were retrospectively studied. According to three different doses of high, middle and low doses of single saliva tetrahexosylganglioside sodium, the clinical efficacy and adverse reactions were observed before and after treatment. The result is 1: 1. After one week of treatment, 70 patients in the control group recovered well, 11 patients with moderate disability and 10 patients with severe disability and 26 patients with vegetative survival. The total effective rate was 77.77g. In the high dose group, 98 cases recovered well, 7 cases were moderately disabled, 8 cases were severely disabled, 4 cases were vegetative state, the total effective rate was 96.58%. 94 cases of moderate dose therapy recovered well, 9 cases of moderate disability 9 cases of severe disability, 5 cases of vegetative survival, the total effective rate was 95.72%. In the low dose group, 85 cases recovered well, 10 cases with moderate disability, 9 cases with severe disability, 13 cases with vegetative survival, the total effective rate was 88.88%. It can be seen that the total efficiency of the treatment group is significantly higher than that of the total effective dose and the therapeutic effect, and the difference is statistically significant (P 0.05). After treatment, the four groups were compared in intracranial pressure, systolic blood pressure and diastolic blood pressure, the difference was not statistically significant (P 0.05). 2. The indexes of acute intracerebral hemorrhage in the four groups were significantly different (P < 0.05). There was no significant difference before treatment in acute cerebral infarction group (P 0.05). NIHSS score and Barthel index score in statistical treatment group and control group were significantly different after treatment. NIHSS score and Barthel index score in four groups were significantly higher than those in control group before and after treatment. The difference between NIHSS score and Barthel Index score was statistically significant (P < 0.05). The total effective rate of diabetic peripheral neuropathy in the control group was 76.92 and that in the former high and low dose group was 840.The total effective rate was significantly higher than that between the two groups (P 0.05). Conclusion: single saliva tetrahexosylganglioside sodium is effective in improving acute cerebral hemorrhage, acute cerebral infarction, craniocerebral injury and diabetic peripheral neuropathy. The therapeutic effect increased with the increase of dosage, and the rate of adverse reaction increased with the increase of dosage, showing a positive correlation trend. Due to the small number of experimental cases and some shortcomings, there is some uncertainty in the results of this experiment. These conclusions need to be confirmed by a large number of random experimental data.
【學(xué)位授予單位】：重慶理工大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R971

【參考文獻】

相關(guān)期刊論文 前10條

1 裴雪梅;高然;張文武;張國英;萬勝明;;單唾液酸四己糖神經(jīng)節(jié)苷脂對缺氧缺血性腦病患兒血清NSE S-100B的影響[J];中國實用神經(jīng)疾病雜志;2015年04期

2 崔德芝;董男男;劉瑞霞;閆小燕;趙立群;;中藥綜合治療對糖尿病足早期周圍神經(jīng)病變神經(jīng)傳導(dǎo)速度的影響[J];山東醫(yī)藥;2013年09期

3 曲彩紅;秦峰;宋美華;;單唾液酸四己糖神經(jīng)節(jié)苷脂鈉注射液致過敏性休克[J];藥物不良反應(yīng)雜志;2012年03期

4 范永橋;;新生兒缺血缺氧性腦病6-keto-PGF1α、NSE檢測的臨床意義[J];中華全科醫(yī)學(xué);2011年12期

5 原春利;;單唾液酸四己糖神經(jīng)節(jié)苷脂治療新生兒缺氧缺血性腦病療效觀察[J];現(xiàn)代醫(yī)藥衛(wèi)生;2011年16期

6 蔣紅梅;龔燕梅;;神經(jīng)節(jié)苷脂對急性腦出血患者神經(jīng)元特異性烯醇化酶的影響[J];醫(yī)學(xué)綜述;2011年14期

7 王艷萍;王征;朱健;俞云會;許秀坤;李云森;;鞘糖脂研究進展[J];生命科學(xué);2011年06期

8 李威;周軍;廖達光;劉峰;韓永豐;;神經(jīng)節(jié)苷脂在大鼠腦外傷中對GAP-43蛋白表達的影響[J];現(xiàn)代醫(yī)藥衛(wèi)生;2011年11期

9 陳永剛;耿彬;王栓科;王翠芳;劉文忠;馬延超;;神經(jīng)節(jié)苷脂對大鼠脊髓損傷后微管相關(guān)蛋白-2表達的影響及意義[J];中國矯形外科雜志;2011年10期

10 張海嬌;陰懷清;栗紅;武師潤;陰崇娟;;神經(jīng)節(jié)苷脂聯(lián)合參附注射液對新生大鼠缺氧缺血性腦損傷的保護作用[J];中西醫(yī)結(jié)合心腦血管病雜志;2011年05期

，

本文編號：2018083